ID
32061
Descrição
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form contains Contraindications to subsequent vaccination. Depending on the subset, the relevant/applicable items need to be checked prior to any vaccination during the study (Visits 1 - 5). Visit 1 -> Timing: Day 0, Age: 6 weeks +/- 1 week; OPV for all subjects Visit 2 -> Timing: Day 30, Age: 10 weeks +/- 1 week; OPV for subset of HRV/HRV-PI alone Visit 3 -> Timing: Day 45, Age: 12 weeks +/- 1 week; OPV for subset of HRV/HRV-PI + OPV, HRV for all subjects Visit 4 -> Timing: Day 60, Age: 14 weeks +/- 1 week; OPV for subset of HRV/HRV-PI alone Visit 5 -> Timing: Day 75, Age: 16 weeks +/- 1 week; OPV for subset of HRV/HRV-PI + OPV, HRV for all subjects
Link
https://clinicaltrials.gov/ct2/show/NCT00139334
Palavras-chave
Versões (2)
- 16/10/2018 16/10/2018 - Sarah Riepenhausen
- 16/10/2018 16/10/2018 - Sarah Riepenhausen
Titular dos direitos
GlaxoSmithKline
Transferido a
16 de outubro de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334
Contraindications to subsequent vaccination
- StudyEvent: ODM
Descrição
Contraindications to subsequent Vaccination: GSK Biologicals' HRV vaccine or its placebo
Alias
- UMLS CUI-1
- C0522473
- UMLS CUI-2
- C0597418
Descrição
This adverse event (AEs) constitutes an absolute contraindication to further administration of HRV vaccine or placebo; if this AE occurs during the study, the subject must not receive additional doses of vaccine but may continue other study procedures at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE:
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C0597418
Descrição
This adverse event (AEs) constitutes an absolute contraindication to further administration of HRV vaccine or placebo; if this AE occurs during the study, the subject must not receive additional doses of vaccine but may continue other study procedures at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE:
Tipo de dados
boolean
Alias
- UMLS CUI [1]
- C0021933
Descrição
This AE constitutes a contraindication to administration of HRV vaccine or placebo at that point in time; if this AE occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.
Tipo de dados
boolean
Alias
- UMLS CUI [1]
- C1531924
- UMLS CUI [2]
- C0489749
Descrição
This AE constitutes a contraindication to administration of HRV vaccine or placebo at that point in time; if this AE occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.
Tipo de dados
boolean
Alias
- UMLS CUI [1]
- C0017160
Descrição
Contraindications to subsequent Vaccination: GSK Biologicals’ OPV
Alias
- UMLS CUI-1
- C0522473
- UMLS CUI-2
- C0032375
Descrição
The following adverse event associated with OPV immunisation constitutes an absolute contraindication to further administration of OPV vaccine; if this adverse event occurs during the study, the subject must be withdrawn and must be followed until resolution of the event as with any adverse event:
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C0027603
- UMLS CUI [2,1]
- C0020517
- UMLS CUI [2,2]
- C0042210
- UMLS CUI [2,3]
- C1705248
- UMLS CUI [3,1]
- C0332300
- UMLS CUI [3,2]
- C0027603
- UMLS CUI [3,3]
- C0011616
Descrição
The following adverse event associated with OPV immunisation constitutes an absolute contraindication to further administration of OPV vaccine; if this adverse event occurs during the study, the subject must be withdrawn and must be followed until resolution of the event as with any adverse event:
Tipo de dados
boolean
Alias
- UMLS CUI [1]
- C0398686
- UMLS CUI [2]
- C0398795
- UMLS CUI [3,1]
- C0332300
- UMLS CUI [3,2]
- C0019693
Descrição
Precaution
Tipo de dados
boolean
Alias
- UMLS CUI [1,1]
- C0743842
- UMLS CUI [1,2]
- C0205082
- UMLS CUI [2]
- C0011991
- UMLS CUI [3,1]
- C0042963
- UMLS CUI [3,2]
- C0205322
Similar models
Contraindications to subsequent vaccination
- StudyEvent: ODM
C0597418 (UMLS CUI-2)
C0597418 (UMLS CUI [1,2])
C0489749 (UMLS CUI [2])
C0032375 (UMLS CUI-2)
C0027603 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0042210 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
C0332300 (UMLS CUI [3,1])
C0027603 (UMLS CUI [3,2])
C0011616 (UMLS CUI [3,3])
C0398795 (UMLS CUI [2])
C0332300 (UMLS CUI [3,1])
C0019693 (UMLS CUI [3,2])
C0205082 (UMLS CUI [1,2])
C0011991 (UMLS CUI [2])
C0042963 (UMLS CUI [3,1])
C0205322 (UMLS CUI [3,2])